Territorial Availability: Available through Bertin Technologies only in France
- Correlated keywords
- western blotting blots signaling signalling WB IHC immunohistochemistry formalin-fixed paraffin-embedded sections controls proteins cannabinoids receptors G-proteins coupled active components cannabis D9- .DELTA.9- DELTA9-trahydrocannabinol splice variant CB1A brain CB2 peripheral tissues spleen hematopoietic cells
- Product Overview:
To be used in conjunction with Cayman’s CB1 Receptor (C-Term) polyclonal antibody (Item No. 10006590) to block protein-antibody complex formation during immunochemical analysis of CB1 · The CB1 receptor is a G-protein coupled receptor that binds the active component of cannabis, ?9-tetrahydrocannabinol.{6749,6747} Human and rat CB1 receptors exhibit 97.3% homology at the amino acid level over the complete protein, and 100% homology within the peptide sequence used to make the Cayman CB1 Receptor polyclonal antibody (Item No. 10006590).{6629,6628} This peptide exhibits no homology with the CB2 receptor. Based on the amino acid sequence, the CB1 receptor has a molecular weight of approximately 52,800.{6628} The CB1 receptor and the splice variant CB1a are localized mainly in the brain whereas the CB2 receptor is localized predominantly in peripheral tissues, including the spleen and hematopoietic cells.{6629,6628,6726,6727}
Cayman Chemical’s mission is to help make research possible by supplying scientists worldwide with the basic research tools necessary for advancing human and animal health. Our utmost commitment to healthcare researchers is to offer the highest quality products with an affordable pricing policy.
Our scientists are experts in the synthesis, purification, and characterization of biochemicals ranging from small drug-like heterocycles to complex biolipids, fatty acids, and many others. We are also highly skilled in all aspects of assay and antibody development, protein expression, crystallization, and structure determination.
Over the past thirty years, Cayman developed a deep knowledge base in lipid biochemistry, including research involving the arachidonic acid cascade, inositol phosphates, and cannabinoids. This knowledge enabled the production of reagents of exceptional quality for cancer, oxidative injury, epigenetics, neuroscience, inflammation, metabolism, and many additional lines of research.
Our organic and analytical chemists specialize in the rapid development of manufacturing processes and analytical methods to carry out clinical and commercial GMP-API production. Pre-clinical drug discovery efforts are currently underway in the areas of bone restoration and repair, muscular dystrophy, oncology, and inflammation. A separate group of Ph.D.-level scientists are dedicated to offering Hit-to-Lead Discovery and Profiling Services for epigenetic targets. Our knowledgeable chemists can be contracted to perform complete sample analysis for analytes measured by the majority of our assays. We also offer a wide range of analytical services using LC-MS/MS, HPLC, GC, and many other techniques.
Accreditations
ISO/IEC 17025:2005
ISO Guide 34:2009
Cayman is a leader in the field of emerging drugs of abuse, providing high-purity Schedule I-V Controlled Substances to federally-licensed laboratories and qualified academic research institutions for forensic analyses. We are certified by ACLASS Accreditation Services with dual accreditation to ISO/IEC 17025:2005 and ISO Guide 34:2009.